
==== Front
J Intensive Med
J Intensive Med
Journal of Intensive Medicine
2097-0250
2667-100X
Elsevier

S2667-100X(24)00037-9
10.1016/j.jointm.2024.03.001
Review
Severe respiratory syncytial virus disease
Peña-López Yolanda 123
Sabater-Riera Joan jsabater@bellvitgehospital.cat
45⁎
Raj Prithvi 1
1 Microbiome Research Laboratory (MRL), Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 Pediatric Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
3 Global Health eCore, Vall d'Hebron Institute of Research, Barcelona, Spain
4 Intensive Care Department, Servei de Medicina Intensiva, IDIBELL-Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona, Spain
5 Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
⁎ Corresponding author: Joan Sabater-Riera, Intensive Care Department, Servei de Medicina Intensiva, IDIBELL-Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona 08907, Spain. jsabater@bellvitgehospital.cat
20 4 2024
10 2024
20 4 2024
4 4 405416
30 10 2023
5 3 2024
5 3 2024
© 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association.
2024

https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The burden of respiratory syncytial virus (RSV) disease is widely recognized. Main risk factors for severe disease, such as extreme ages, chronic cardiopulmonary conditions, and immunosuppression, typically coincide with poorer outcomes. While the majority of RSV hospitalizations involve healthy children, a higher proportion of hospitalized adults with underlying conditions need intensive care. Presently, treatment primarily consists of supportive measures. RSV-induced wheezing should be distinguished from respiratory tract thickening, without response to bronchodilators. Obstructive RSV disease frequently overlaps with viral pneumonia. Non-invasive mechanical ventilation and high-flow oxygen therapy represented significant advancements in the management of severe RSV disease in children and may also hold considerable importance in specific phenotypes of RSV disease in adults. Most severe infections manifest with refractory hypoxemia necessitating more advanced ventilatory support and/or extracorporeal membrane oxygenation therapy. Although bacterial co-infection rates are low, they have been associated with worse outcomes. Antibiotic prescription rates are high. Accurately diagnosing bacterial co-infections remains a challenge. Current evidence and antibiotic stewardship policies advise against indiscriminate antibiotic usage, even in severe cases. The role of currently developing antiviral therapies in severe RSV disease will be elucidated in the coming years, contingent upon the success of new vaccines and immune passive strategies involving nirsevimab.

Keywords

RSV
Bronchiolitis
Co-infection
Pneumonia
ARDS
Respiratory failure
Managing Editor: Jingling Bao/Zhiyu Wang
==== Body
pmcIntroduction

In the post-pandemic era, a shift in seasonal pattern and severity of respiratory syncytial virus (RSV) has been reported worldwide[[1], [2], [3]] in addition to the RSV disease burden in the adult population.[[4], [5], [6]] The immunity gap due to the pandemic measures, an increased RSV virulence, and a potential interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and RSV along with the persistent immunological dysfunction following coronavirus disease 2019 (COVID-19) are the proposed reasons for this increase of RSV infection and severity,[[7], [8], [9]] apart from its raising awareness.[10] Hönemann et al.[3] reported a mean age significantly younger in the post-pandemic adult RSV cohort (47.1 years vs. 64.7 years) compared to pre-pandemic seasons. Furthermore, concerns regarding the burden of severe RSV disease among immunocompromised adults and children have persisted since pre-pandemic years.[11,12]

While existing definitions largely agree on cases of lower respiratory tract infections (RSV-LRTI), there remains a necessity to establish a standardized definition for severe RSV disease.[13] Severity assessment typically relies on criteria such as oxygen requirement, hospitalization, escalation of respiratory support, or intensive care unit (ICU) admission (Table 1). Clinical scores in children[14] and adults[15] are designed to predict the need for respiratory support mainly, but lack sufficient validation.[14] The aim of this narrative review is to depict risk factors and phenotypes of severe RSV disease that are critical for its current management. For the purposes of this review, severe RSV disease will be defined as extended severe acute respiratory infection proposed by the World Health Organization global surveillance system for RSV.[16] Comprehensive updates on recently approved vaccines, monoclonal antibody use for prevention,[17] and ongoing advances in investigational therapeutic drugs[18] have been extensively covered in recent publications and are beyond the scope of the present review.Table 1 RSV Severity definition and risk factors.

Table 1Author (year)	Case number	Population	Clinical setting	Severity definition	Risks factors and other findings	
Grimaldi et al. (2002)[31]	484	<1 year	General ward	Pediatric ICU admission	Term newborn (OR=0.86, 95 % CI: 0.75 to 0.98), neonatal distress syndrome (OR=4.23, 95 % CI:1.31 to 13.03), congenital heart disease (OR=5.26, 95 % CI:1.02–21.01)	
Flamant et al. (2005)[58]	151	<1 year
Mechanically ventilated	Pediatric
ICU	Prolonged MV (>6 days)
ECMO support	<32 GA (aOR=4.2, 95% CI:1.3 to 13.7), 33–36 GA (aOR=2.5, 95% CI:1.1 to 6.2), oxygen supplementation (aOR=3.4, 95% CI:1.2 to 10.4]), BPD (aOR=11.9, 95% CI:1.4 to 10.0),
bacterial colonization* (OR= 3.4, 95% CI:1.5 to 7.7)
Only independent risk factor for ECMO support BPD (aOR=11.8, 95% CI: 2.2 to 63.1)	
Ciarlitto et al. (2019)[47]	422	<1 year	General ward	Oxygen supplementation
Pediatric ICU admission	RSV-A caused most of severe cases in the premature group
Increased bronchiolitis severity over the years	
Heinonen et al. (2019)[41]	1,042,045	<1 year	Population-based cohort	Hospital admission	Transient tachypnea of the newborn (OR=1.31, 95% CI:1.16 to 1.48)	
Shmueli et al. (2019)[30]	1124	<2 years	General ward	Hospitalization LOS
PICU admission
PICU readmission rate	Chronic diseases
Down's syndrome
Respiratory tract malformation	
Meenaghan et al. (2020)[42]	557	≤2 years	General ward	PICU admission	Younger age, being underweight at the point of admission (aOR=3.15, 95% CI:1.46 to 6.70), the use of HFNC	
Zhang Y et al. (2020)[54]	574	≥18 years	General ward	ICU admission
Invasive MV	Influenza-RSV virus co-infection (47.4%) vs. only RSV (20.1%) (P=0.004)
Influenza-RSV virus co-infection (47.4%) vs. only RSV (13.2%) (P <0.001)	
Nygaard et al. (2023)[32]	310,423	<18 years	Population-based cohort	Hospital admission
MV	Increased severe RSV disease between the epidemic period (2020–2021) compared with the pre-COVID-19 seasons, mostly among children aged 24–59 months	
Celante et al. (2023)[22]	1168	>18 years	General ward	Invasive MV	Chronic heart failure (aOR=1.98, 95% CI:1.20 to 3.26), respiratory failure (aOR=2.83, 95% CI:1.67 to 4.80), co-infection (aOR=2.62, 95% CI:1.60 to 4.30)	
Hill-Ricciuti et al. (2023)[33]	244	>18 years	General ward	Respiratory support escalation
Need for MV
ICU admission	Hospital-acquired-RSV patients at higher risk for escalation resp support and chronic disease, less pulmonary conditions. Obesity.
Community-acquired RSV, more pulmonary conditions	
Saiman et al. (2023)[34]	122	≤18 years	General ward	Increased respiratory support
Pediatric ICU admission	Respiratory comorbidities (aOR=3.36) for increased respiratory support	
Kobialka et al. (2023)[100]	594	≤2 years	General ward	Oxygen therapy
Respiratory failure
PICU admission
Prolonged hospital LOS	Bacterial pneumonia: Fever duration (OR=1.70, 95% CI:1.31 to 2.26), aspiration (OR=40.75, 95% CI:5.94 to 444.64), CRP (OR=1.06, 95% CI:1.02 to 1.10), PCT (OR=0.61, 95% CI:0.38 to 0.95), hypercapnia (OR=4.36, 95% CI:1.56 to 11.97)
Respiratory failure: Apnea (OR=29.37, 95% CI: 3.12 to 231.43)
Oxygen therapy: Apgar (OR=1.60, 95% CI:1.06 to 2.58), breastfeeding (OR=0.49, 95% CI: 0.26 to 0.92), dyspnea (OR=5.22, 95% CI: 2.43 to 12.51)	
Descamps et al. (2022)[62]	539	>18 years	General ward	Respiratory failure, ARDS, ICU admission, invasive MV	Compared to influenza-positive hospitalized patients, RSV-positive hospitalized patients had higher adjusted risk for developing respiratory failure (aPR=1.6, 95% CI:1.1 to 2.3), ARDS (aPR=2, 95% CI:1.3 to 3.1), ICU admission (aPR=2, 95% CI:1.4 to 2.9), invasive MV (aPR=1.7, 95% CI:1.1 to 2.4).	
Coussement et al. (2022)[37]	618	>18 years	ICU	ICU admission	Patients with RSV infection were significantly more likely to have an underlying chronic respiratory condition (60.2% vs. 40.1%; P <0.001) and to be immunocompromised (35% vs. 26.2%; P=0.02) than patients with influenza infection. Several differences in clinical signs and biological data at diagnosis were found between the groups. In-hospital mortality was not significantly different between the two groups (23.9% in the RSV group vs. 25.6% in the influenza group; P=0.63), even after adjustment for prognostic factors in a multivariate model	
Sivgin et al. (2023)[39]	46	>18 years	General ward	Parenquimal infiltrates + oxygen supplementation (starting if oxygen saturation <90%)	Age (OR=1.17, 95% CI:1.06 to1.28 per unit change of age); hypertension (OR=13.9, 95% CI:2.5 to 75.9), diabetes (OR=17.4, 95% CI:3.4 to 87.5), heart failure (OR=10.3, 95% CI:2 to 53.2), bacterial co/superinfection (OR=15, 95% CI:3.1–73.6)	
Tongyoo et al. (2023)[57]	335	>18 years	ICU	MV	RSV group had significantly higher proportions of bronchospasm (98.5% vs. 60.8%; P <0.001), ventilator-associated pneumonia (52.2% vs. 33.8%; P=0.005), and lung atelectasis (10.4% vs. 3.0%; P=0.009) than the non-RSV group.	
Kim et al. (2023)[12]	257	>18 years	ICU	ICU admission	Structural lung disease, diabetes mellitus, and malignancy were common underlying diseases in RSV group and influenza group, with no statistically significant differences
Immunocompromised state (57.6% vs. 34.4%; P <0.001) and hospital acquisition (47.8% vs. 23.9%; P <0.001) were significantly more common in the RSV group.
Co-infection with Streptococcus pneumoniae (3.3% vs. 9.8%; P=0.08) and methicillin-susceptible Staphylococcus aureus (1.1% vs. 6.8%; P=0.06) tended to be less frequent in the RSV group compared to influenza group.
The 90-day mortality was high in both groups (39.1% vs. 40.5%; P=0.89).	
⁎ Identification of positive tracheal aspiration culture.

aHR: Adjusted hazard ratio; aOR: Adjusted odds ratio; aPR: Adjusted prevalence ratio; ARDS: Acute respiratory distress syndrome; BPD: Bronchopulmonary dysplasia; CI: Confidence interval; COVID-19: Coronavirus disease 2019; CRP: C reactive protein; ECMO: Extracorporeal membrane oxygenation; GA: Gestational age; HFNC: High-flow nasal cannula; ICU: Intensive care unit; LOS: Length of stay; MV: (invasive) Mechanical ventilation; OR: Odds ratio; PCT: Procalcitonin; PICU: Pediatric intensive care unit; RSV: Respiratory syncytial virus.

Epidemiology

Previously, healthy children <5 years represent the majority of RSV hospitalizations in childhood with low rates of intensive care admissions (2.3%) but higher and longer ICU stay compared with other viruses, including SARS-CoV-2.[10,[19], [20], [21]] Hospitalized RSV-infected adults and seniors (≥ 60-year-old) account for only 1% and 4% of the overall hospitalizations,[10] respectively, yet present higher proportions of underlying comorbidities (78%–90%) and have 5–10 fold increased risk for ICU admission (12%–26.9%) compared to children.[10,[22], [23], [24]] Among adults, the risk for ICU admission was higher for RSV compared to influenza (odds ratio [OR]=1.6) but lower than for SARS-CoV-2 (OR=0.37),[25] prior to the emergence of the Omicron variant and the introduction of COVID-19 vaccines. Recent data indicated that among hospitalized seniors, RSV was still less common, but associated with more severe disease than SARS-CoV-2 (adjusted odds ratio [aOR]=1.49) or influenza (aOR=1.55).[26] According to the RSV-Associated Hospitalization Surveillance Network and the overall RSV-ICU admission rates reported[10] among 605.2 hospitalizations per 100,000 <5 year-children and 90.9 per 100,000 adults during the 2022–2023 season, the overall estimated ICU admission rates were 13.2 per 100,000 children <5 years and 19.2 per 100,000 per adults. Among RSV-immunocompromised hospitalized patients, 28% for children[27] and 36% for adults.[28]

Risks Factors for Severe RSV Disease

Frequently, risk factors for RSV hospital admission overlap with risk factors for worse outcomes (Table 2). Age (younger than 3 months or >60 years) and chronic cardiopulmonary conditions have been defined as the main risk factors for severe RSV disease.[10,[22], [23], [24],[29], [30], [31], [32], [33], [34]] Hospitalization rates among senior adults were up 9-fold higher compared to other adults.[35] In comparison to influenza infection, adults with chronic obstructive pulmonary disease (COPD) were more susceptible to RSV infection and mechanical respiratory support.[36] Adult patients in the ICU with RSV infection also differ from adult patients with influenza, being more likely to have an underlying chronic respiratory condition and to be more immunocompromised.[37] Apart from immunocompromised status,[10,23,24] other RSV-high risk comorbidities described in adults include chronic renal disease and diabetes,[23,38] even in middle-aged RSV patients.[39] Surprisingly, Chatzis et al.[40] reported that adults with solid tumors (OR=5.2) or those requiring chronic immunosuppressive treatments, mainly for rheumatologic conditions (OR=4.1), were significantly more likely to be admitted to the hospital compared to hematopoietic stem cell (HSCT) recipients. This may be explained by a higher adherence to preventive measures among HSCT patients.Table 2 RSV disease severity: Changes in microbiome, potential pathogenic bacteria detection, and viral factors.

Table 2:Author (year)	Case number	Samples	Sample collection	Assays	Endpoint	Population	Findings	
Flamant et al. (2005)[58]	151	Tracheal aspirates	Once at admission (first 24 h of MV)	Culture	RSV severity Prolonged MV (>6 days)	Children <1 year Mechanically ventilated RSV children	Positive ETA culture (OR=3.4, 95% CI:1.5 to 7.7) (bacterial colonization)	
Munywoki et al. (2015)[49]	205	Deep nasopharyngeal swabs	Twice/week 6-month follow-up	qPCR Genomic sequencing	RSV-load dynamics
Factors influencing the rates for recovery from RSV infection	Naïve infants and households	Age (<1 year ref.)
1–4 years (HR=1.98, 95% CI:1.30 to 3.02)
5–14 years (HR=1.82, 95% CI:1.16 to 2.87)
≥15 years (HR=1.97, 95% CI:1.11 to 3.51)
Detection of other viruses*,†
Before RSV episode (HR=1.56, 95% CI:1.02 to 2.39)
During RSV episode (HR=0.48, 95% CI:0.32 to 0.73)
Other household members infected (%)
≥33–66% (HR=0.59, 95% CI:0.40 to 0.87)
>66% (HR=0.51, 95% CI:0.35 to 0.74)	
Hasegawa et al. (2017)[94]	11,016	Nasopharyngeal aspirates	Once at hospital admission (first 24 h)	16 s sequencing	RSV severity (PICU admission admission)	<1 year-old (Inpatient)	Changes in microbiota associated with RSV severity in the group with IL-37 lower levels	
Brealey (2018)[90]	58	Nasal swabs or nasal washes	Twice.
At the emergency room and 8 weeks after	qPCR	RSV severity (Bronchiolitis score)	<2 years
Emergency department
Mild comorbidities included	Higher severity scores associated with RSV and S. pneumoniae co-detection.
Not associated with admission to hospital and the use of supplemental oxygen	
García-Mauriño et al. (2019)[51]	150	Nasal midturbinate swabs	Daily	qPCR	Viral load dynamics
RSV severity (bronchiolitis score, supplemental oxygen, PICU admission, Hospital LOS)	Previously healthy <2 years (Inpatient/outpatient)	Outpatients higher viral loads than inpatients
Faster and consistent viral clearance associated with lower oxygen needs	
Harding et al (2020)[89]	95	Stool samples	Within 72 h of admission	16 s sequencing	RSV severity (PICU admission)	<1 year-old (Inpatient)
Mild comorbidities included	Gut microbiome alpha diversity lower in severe RSV
Gut microbiome beta diversity different among groups non-RSV/moderate RSV/severe RSV	
Brealey (2020)[93]	54	Nasal swabs	Weekly	qPCR	Bacterial colonization dynamics associated with RSV
during early childhood	<2 years
A prospective longitudinal birth cohort	S. pneumoniae and M. catarrhalis co-detection was frequent during RSV episode (61.1% and 48.1% respectively)
In most cases, S. pneumoniae and M. catarrhalis preceded the viral infection, with the nasal load of each increasing during RSV infection	
Diaz-Diaz et al. (2022)[103]	681	Nasopharyngeal and midturbinate swabs	Once at hospital admission
At 24 h (18–34) from hospital admission	qPCR	RSV severity
(Hospital admission and LOS, oxygen need, bronchiolitis score)	Previously healthy <2 years
(Inpatient/outpatient)	Codetection S. pneumoniae and H. influenzae increased the risk for severe RSV disease
Hospitalization (OR=2.2, 95% CI:1.07 to 4.74)
Bronchiolitis score (OR=1.93, 95% CI:1.14 to 3.26)
Oxygen need (OR=2.23, 95% CI:1.01 to 4.91)
Hospital LOS (OR=2.53, 95% CI:1.33 to 4.79)	
Cuthbertson et al. (2022)[96]	37	Nasal wash samples
Oropharyngeal swabs	Daily (first 10 days) at day 14 and 28 post-RSV inoculation	qPCR
16 s sequencing	RSV infection (non-infection, asymptomatic, clinical cold)	Previously healthy non-smoking subjects 18–50 year-old	Significant viral loads differences between uninfected and infected at days 5, 6, 7, 8 (P ≤0.001)
Day 3 viral load increased in patients who went on to develop symptoms; Day 7 peak of infection and viral load fell thereafter.
Bacterial load in the asymptomatic infected group fluctuated more than in the other groups in the first 4 days of infection.
No significant differences in bacterial load, alpha diversity measures or species turnover among groups over the course of viral infection	
⁎ Detection of other respiratory viruses during the 14 days prior to the start of RSV episode only.

† Other viruses were adenoviruses, rhinoviruses, and coronaviruses no SARS-CoV-2.

CI: Confidence interval; ETA: Endotracheal aspirate; HR: Hazard ratio; IL: Interleukin; LOS: Length of stay; MV: Mechanical ventilation; OR: Odds ratio; PICU: Pediatric intensive care unit; qPCR: Quantitative polymerase chain reaction; RSV: Respiratory syncytial virus; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Among infants, a history of prematurity, low birth weight, or transient tachypnea of the newborn[[41], [42], [43]] was associated with severe RSV disease. Other higher-risk comorbidities in young children and infants, apart from cardiopulmonary conditions, include Down syndrome, neuromuscular, and metabolic disorders.[44,45] Nevertheless, most infants who require intensive care for RSV low respiratory tract infections are healthy and born at term.[46]

Viral factors may actively contribute to the clinical severity of RSV infection.[[47], [48], [49]] Serotype A is more prevalent and causes more severe cases in born–preterm infants.[47] Among adults, no clustering has been found according to severity.[50] A faster decline of viral loads is indicative of less severe RSV disease.[51] The role of viral co-detections remains unclear, and only RSV-human metapneumovirus co-infection was associated with a higher risk of ICU admission (OR=7.2) in children.[52] Interestingly, RSV and human metapneumovirus are very closely related viruses.[53] In adults, co-infection of RSV and influenza virus has been associated with higher rates of ICU admission, mechanical ventilation (MV), and mortality.[54]

Clinical Phenotypes of Severe RSV Infection: Wide Clinical Overlapping Phenotypes and Lack of Uniform Criteria

Bronchiolitis, bronchitis, viral pneumonia

Severe RSV disease manifests as acute-LRTI that can lead to respiratory failure and ICU admission across all age groups.[10] The typical diagnoses that belong to LRTI include bronchitis, bronchiolitis, and pneumonia. In newborns and infants up to 2 years old, its most specific manifestation is acute bronchiolitis, with subsequent episodes of RSV-induced wheezing/bronchitis occurring after the first RSV-infectious episode.[10,13,55] Children or adults with chronic cardiopulmonary conditions may also experience episodes of acute pulmonary decompensation, manifested by tachypnea, worsening gas exchange (e.g., increased oxygen requirement), and/or respiratory distress.

During a 10-year period, Niekler et al.[10] reported 49.5% of RSV-pneumonias in children, 62.9% in adults aged 18–59 years, and 60.2% in senior RSV-hospitalized patients. RSV-pneumonia, which often co-exists with obstructive phenotypes, can also progress to hyperinflammatory responses and pulmonary tissue damage, leading to acute respiratory distress syndrome (ARDS) at any age.[10] Notably, Estofolete et al.[56] found no significant differences in the manifestation of RSV between adult and senior patients, with wheezing and atelectasis being more common in RSV- compared to influenza-infected adults.[57] While certain groups of immunocompromised patients such as lung transplant and HSCT recipients are at higher risk for refractory hypoxemia and ventilator support, most severe RSV infections in the ICU often correspond to complicated viral pneumonias with bacterial co-infection and/or ARDS, even among immunocompetent non-senior adults[37] and previously healthy infants initially diagnosed with “simple” bronchiolitis.[13,58] This is consistent with data from two multicenter prospective studies showing no association between the day of illness admission and hospital outcomes among infants diagnosed with RSV-bronchiolitis, refuting a predictable disease trajectory and supporting the concept of overlapping phenotypes, particularly in severely hypoxemic cases.[46,59,60]

Additionally, there is a growing need for a more precise distinction between obstructive disease resulting solely from the respiratory tract thickening and secretions – without response to bronchodilators – and those exhibiting RSV-induced wheezing.[61]

ARDS

Reported ARDS incidence rates among hospitalized RSV-adults range between 0.7% and 9%, increasing to 20.4% among those requiring ICU admission.[10,37,62] It is noteworthy that a significant proportion of adult studies may have underestimated RSV-infection and RSV-induced ARDS due to the lack of routine testing.[[63], [64], [65], [66], [67]] In immunocompromised adults, particularly those with hematologic malignancies, there is a description of rapidly progressive severe bilateral pneumonia leading to ARDS,[68] a condition not limited to this population. Few studies have accurately reported the frequency of RSV-induced pediatric ARDS in infants and its impact on prognosis. Among hospitalized RSV-children, Niekler et al.[10] reported an ARDS incidence of 0.1%. However, among RSV-children under 2 years admitted to the ICU, the incidence of ARDS has been reported to be around 20% (7% for severe pediatric-ARDS, up to 33% among children with RSV and acute -or acute-on-chronic- respiratory failure).[21,69] Despite ARDS being more common among children with RSV than those with other viruses,[21] the clinical course, risk factors, and outcomes of RSV-induced pediatric-ARDS do not seem to differ from other virus types.[69] In contrast to the lower mortality rates of overall RSV-infections in the pediatric ICU (5.4%–12.94%)[54] mortality rates from 40% to 70% have been reported in pediatric patients with ARDS,[70,71] similar to the adult population.[72,73] Overall mortality among RSV-hospitalized adult patients (4%–9%)[10,23,62] was close to mortality rates of critically ill RSV-pediatric patients.

Risk factors for MV and RSV-mortality

Shortness of breath on presentation and the need for supplemental oxygen are associated with severe disease in both populations.[14,24,74] Although immunosuppressed patients bear the greatest relative burden of RSV hospitalizations (1288–1562 per 100,000 immunocompromised patients),[35] no pre-existing condition was significantly overrepresented compared to others in adult and senior patients requiring ICU admission.[24,28] Among critically ill patients, bacterial co-infection/superinfection and ARDS were the main factors associated with the need of MV and mortality across all ages and underlying conditions.[24,40,57,58,75,76] Among adults admitted to the ICU due to respiratory failure, mortality in those infected with RSV did not differ from that in patients admitted without RSV infection despite their higher incidence of complications such as bronchospasm, ventilator-associated pneumonia, and lung atelectasis.[57] Although infants with a history of birth before 37 weeks had a 1.5-fold higher risk of requiring ventilation compared to those born at term,[43] mortality did not differ significantly between them in the era of palivizumab and ECMO support. No specific risk factors for the need of MV and mortality have been described for immunocompromised RSV-children or adults requiring ICU admission beyond their underlying condition or extreme ages of life.[22,40,77] Moreover, among 370 immunocompromised adults with virus-detected acute respiratory failure, the type of virus (14% RSV) was not associated with mortality. Furthermore, after matching, patients with virus-detected acute respiratory failure had lower mortality (OR=0.77) than immunocompromised patients suffering from other causes of acute respiratory failure, with an in-hospital mortality of 26%.[77]

According to death certificate data from RSV-associated deaths in the United States,[78] among children under 5 years, the cause of death was nearly evenly divided between RSV-bronchiolitis (50.6%) and RSV-pneumonia (46.4%), whereas the code for RSV-pneumonia was assigned for almost all (90.8%) of the RSV-associated deaths among those children aged 5 years and older and in adults. RSV-bronchitis as a cause of death was rarely documented in any age group.

Extrapulmonary manifestations of severe RSV infection

In infants up to 3 months, severe RSV disease can also present as a central apnea with few respiratory symptoms or sudden death (16%–21% admissions), especially in those who were preterm-born.[79] Other non-specific clinical signs in young infants include lethargy and hydroelectrolytic disturbances. Confusion and disorientation might be frequent in adults, particularly the elderly. Hyponatremia is a common extrapulmonary manifestation of RSV that has been related to an increased antidiuretic hormone secretion in both populations.[79,80]

Direct myocardial injury with the need of inotropic support or arrhythmias has also been described in both populations. [81,82] Interestingly, elevated aspartate aminotransferase levels on admission (but not elevated alanine aminotransferase levels) were associated with longer ventilation periods and ICU length of stay (LOS) in previously healthy infants with RSV-bronchiolitis on invasive MV.[83] N-terminal prohormone of brain natriuretic peptide (NT-proBNP) has been suggested as a biomarker for RSV-bronchiolitis severity and cases complicated by acute cardiac failure.[84] The higher cardiovascular morbidity and mortality among RSV-infected adults (up to 45% a history of underlying heart disease, 16.7% mortality related to an acute cardiovascular event) has also led to the hypothesis of a direct damage.[85,86] Hepatitis, defined as transient transaminase elevation, is frequently reported, with rates up to 46%–49% in ventilated infants.[79,87] While most of these findings may be explained by secondary damage, hepatic involvement should alert to screening for heart disease-causing ischemic hepatitis in the light of the above. [86]

Systemic dissemination of the virus during severe disease, sepsis-like with fatal development, has also been reported in young infants.[88] RSV was found in meningeal swabs, cerebrospinal fluid, myocardium, pericardium, abdominal fluids, liver, and brain autopsies.[79]

The Role of the Respiratory Microbiome and Bacterial Co-infections in Severe RSV Disease

There is increasing evidence of a complex interplay between the microbiome, innate immunity, and viral infections causing severe pulmonary disease (Figure 1).[[89], [90], [91], [92]] Changes in the upper airway microbiota diversity may precede most clinically significant RSV infections in children.[93] Co-detection of potentially pathogenic bacteria in lower respiratory samples within the first 24 h after intubation also was associated with prolonged MV among them.[58] Nevertheless, distinguishing between colonization and true lower bacterial respiratory infection remains challenging. Hasegawa et al.[94] reported that associations between microbiota profile and severe RSV disease differed by the status of the interleukin (IL)-37, a cytokine transducing anti-inflammatory signals.[95] Among infants with lower IL-37 levels, Haemophilus-dominant profile was associated with a higher risk of ICU use (aOR=4.14). Conversely, with higher IL-37 levels, no significant associations between microbiota profiles and risk of ICU admission were found. It is plausible that microbiota regulate the immune response to RSV, among other factors. In adults, although some microbial signatures have been associated with SARS-CoV-2- and influenza-infection severity and poor clinical outcomes, Cuthbertson et al.[96] failed to find significant changes in the bacterial community over the course of RSV infection. It is worth noting that this study only involved a small number of adults with upper respiratory tract RSV-infection compared to studies among hospitalized children with LRT-RSV disease. As microbial composition within the human respiratory tract is impacted by SARS-CoV-2 and influenza, in both, children and adults, the relative stability of the immune system and microbial community reported in this study would be better explained by the milder disease experienced by these healthy adults rather than a true resilience of the adult respiratory microbiome against RSV. Interestingly, bacterial microbiome load in the asymptomatic infected group fluctuated more than in the other groups in the first days of infection. Relative abundances of potential protective bacteria were not provided.Figure 1 Microbiome-RSV interactions and other host & viral-related factors.

RSV: respiratory syncytial virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Fig 1

On the other hand, silent micro-aspirations are more common than previously acknowledged among previously healthy children with RSV-bronchiolitis.[97] They have been associated with a decrease in oxygen saturation[98] and rapid deterioration,[99] leading to aspiration pneumonitis and bacterial pneumonia (OR=40.7),[100] which in turn can progress to ARDS. Takahashi et al.[101] reported that up to 20% of the RSV severe pneumonia patients were initially diagnosed as having aspiration pneumonia in an adult cohort, 63% of them corresponding to mixed co-detections with other common respiratory pathogens. It is possible that changes in the lower respiratory tract and lung microbiota may promote complicated interactions that dysregulate immune homeostasis and affect the inflammatory response in the lung.[102] Notably, despite the overall low rates of bacterial co-infections among RSV-hospitalized children (1%–3.5%) and adults (12%), they have been associated with worse outcomes and ARDS development.[21,22,75,76,103]

Current Management of Severe RSV Disease

Despite extensive efforts to develop specific antivirals against RSV, the main therapeutic approach for acute RSV infection remains supportive care. Current evidence-based guidelines for bronchiolitis advice against pharmacological interventions such as corticosteroids, beta2-agonists, and epinephrine.[104] However, there are no specific guidelines for managing each specific phenotype needing intensive care. In RSV-infected adults, the standard of care for managing severe RSV infection mainly involves bronchodilators, supplemental oxygen, intravenous fluid, and antipyretics,[105] with systemic corticoids being associated with bacterial superinfection (aHR=3.1).[76] Thus, the use of bronchodilators and corticosteroids should be carefully considered in selected cases with high suspicion of airway hyperreactivity/RSV-induced wheezing such as positive bronchodilator tests defined by tidal breathing flow-volume loops changes.[106] Fluid restriction and/or isotonic fluids for parenteral therapy have been suggested to avoid hyponatremia.[80] In ventilated RSV-children, avoiding early fluid overload may shorten ventilator periods and ICU LOS.[107]

Respiratory support

In the recent decades, the development of non-invasive mechanical ventilation (NIV) along with high-flow heated and humidified oxygen therapy has decreased the rate of intubation in infants with RSV-bronchiolitis from 50%–60%[71] to 12%–24%.[46,[108], [109], [110]] High-flow nasal cannula (HFNC) support was initially positioned as a rescue therapy for those bronchiolitis not adequately supported by standard oxygen therapy, one step before NIV use. Although there is increasing data indicating the reasonable clinical benefit of early HFNC therapy,[111] the lack of standard practices seems to explain significant variations in respiratory support, ICUs admission rates, and outcomes in infants with moderate–severe bronchiolitis,[47,112,113] raising concerns about its overuse in the ward.[114] Conversely, standardized higher initial HFNC flows (2 mL/kg) and protocolized escalation/weaning practices have been associated with a lower HFNC failure rate and a decreased ICU and hospital LOS in RSV-bronchiolitis patients.[[115], [116], [117]] More studies are needed to determine the impact of HFNC on the number of interhospital transfers, ICU admissions, and its benefit in avoiding NIV in children.[[118], [119], [120], [121]]

In adults, a significantly higher proportion of RSV-hospitalized patients presented respiratory failure compared to influenza-hospitalized patients (31% vs. 16%),[62] and they were also more likely to receive invasive MV or die compared with them (OR=2).[26] In the adult population, HFNC use increased due to COVID-19 patients,[77,82,[122], [123], [124]] reducing the need for intubation compared to standard oxygen therapy, although a reduction in mortality was not demonstrated. It would be logical to extend its use to other common viral lower respiratory tract infection (LTRI) from the community, as RSV or influenza-LTRI. In the pre-COVID era, non-invasive ventilation was discouraged in adult patients with acute hypoxemic failure, only being recommended in mild early acute hypoxemic respiratory failure (partial pressure of oxygen [PaO2] /fraction of inspired oxygen [FiO2] ratio <300 and >200) under close supervision.[125] Otherwise, its main indications were COPD exacerbations with mild acidosis or cardiogenic pulmonary edema taking into account that, especially in elderly patients, RSV can very often be a factor in the decompensation of chronic heart and/or lung disease.[63] In recent years, evidence shows the benefits of its use also in SARS-CoV-2 acute hypoxemic respiratory failure,[126] one successful case being recently reported in a senior patient with RSV-hypoxemic failure.[127] Nowadays, HFNC and NIV may be considered a viable alternative in well-monitored patients when administered by expert groups, balancing the benefits against the potential harms of delaying intubation.

Hypoxemic respiratory failure and viral pneumonia have been associated with a higher likelihood of transition to invasive ventilation than other LTRI phenotypes.[128] Nevertheless, studies focusing on mechanically ventilated children showed that RSV-LRTI behaves as a heterogeneous disease with three distinctive patterns: restrictive, obstructive, or mixed pattern, even when clinically labeled only as bronchiolitis[129] Tongyoo et al.[57] reported higher proportions of bronchospasm and lung atelectasis in RSV-ventilated adults for respiratory failure compared to the non-RSV group (98.5% vs. 60.8%). Strategies for the use of invasive ventilation should be tailored accordingly.[130]

In the absence of specific guidelines for the management of RSV-pneumonia, the “protective ventilation” approach should be employed on the most hypoxemic RSV patients, using low tidal volume ventilation strategies (in the range of 4–8 mL/kg predicted body weight [PBW], depending on lung compliance) along with appropriate levels of positive end-expiratory pressure (PEEP) to limit lung distension and atelectrauma with the goal of maintaining plateau airway pressure. This is below 28–30 cmH2O in adults and ≤28 in children according to the last consensus[131,132] Furthermore, PEEP values may be adjusted according to the dynamic patient's condition and its clinical response, as two ARDS phenotypes with divergent clinical outcomes and differential response to MV have been described.[133]

Hyperinflated RSV-infants benefit from slow rates and long expiratory times.[130] In adults, ventilatory support reducing minute ventilation, low tidal volumes, and prolonged expiratory time to limit hyperinflation has been suggested in obstructive airway disease, independently of its pathogenesis or underlying condition.[134] Interestingly, some authors reported that the elastic component of working pressure was predominant during some severe RSV infections in infants, similar to ARDS pathophysiology, despite not fulfilling ARDS criteria.[70] A personalized and dynamic characterization of the respiratory mechanics at the bedside in RSV patients with apparently the same RSV phenotype but ventilatory mixed patterns (obstructive and restrictive) has been suggested to tailor the ventilator settings according to which component is predominant.[129]

In cases of severe respiratory failure, the consideration of extracorporeal membrane oxygenation (ECMO) support is recommended. Infants suffering from bronchopulmonary dysplasia are at highest risk for it (aOR=11.8).[58] Before the pandemics, ECMO use in RSV-adults was reported in 2.4% of RSV-adults needing intensive care.[10] As ECMO use in adults has increased notably in recent years, this rate is expected to increase if new preventive measures and treatments to address respiratory conditions caused by RSV are not successful. Its administration should be individualized in accordance with the protocols of each medical center.

Prone positioning and mucus clearance strategies

As in COVID and other viral pneumonias, prone positioning would be recommended even in non-intubated patients with a PaO2/FiO2 ratio <150 mmHg and PEEP ≥5 cmH2O, as well as in patients on ECMO support.[135,136] Given that atelectasis and mucus plugging are more frequent in RSV disease than other viruses, ventilation/perfusion mismatch is a significant concern, particularly in young infants. The use of hypertonic saline is broadly reported in this population.[109,137,138] In a meta-analysis of randomized controlled trials,[139] nebulization of 3% saline solution was effective in decreasing the severity of symptoms and hospital LOS compared with 0.9% saline solution. The latest Cochrane update[140] states its safety, although more evidence is needed in the guidelines. Conversely, the use of mucolytics as N-acetylcysteine or dornase-alfa has been strongly discouraged due to the lack of evidence.[141,142] Pharmacological mucus clearance therapies are rarely used in older children and adults with RSV-infection. Current evidence discourages routine normal saline solution lavage for artificial airway suctioning.[143] Moreover, O'Neal et al.[144] documented a significant increase in the level of dyspnea after suctioning senior adults. Conventional and forced expiratory techniques have not demonstrated any impact on outcomes, being even harmful in severe bronchiolitis.[145] In adults, a recent meta-analysis concluded that patients with acute exacerbation of COPD disease may benefit from high-frequency chest wall oscillation therapy.[146] High-frequency chest wall oscillation plus fibrobronchoscope alveolar lavage may also reduce the duration of MV and ICU stay in pneumonia among the adult population.[147] Nevertheless, current evidence is very uncertain about the effects of chest physiotherapy on improving mortality in adults with pneumonia and no data referring specifically to RSV-patients has been reported.[148,149]

Pharmacotherapeutic treatments for selected cases

Ribavirin, a broad-spectrum, non-interferon virustatic chemotherapeutic agent, was the first antiviral treatment approved for severe RSV in children, but only in its aerosolized form. Its routine use was not recommended to prevent MV, ECMO, or death among RSV children due to its limited efficacy, side effects, and potential teratogenic risk for healthcare providers, though. Its use was relegated to immunocompromised patients or severe influenza co-infections.[148,149] Current evidence shows that oral ribavirin is a well-tolerated alternative for endovenous or aerosolized ribavirin, including critically ill adults or children.[150] It may be also a reasonable option to treat hematologic malignancies and HSCT recipients in the absence of other effective antiviral agents.[150,151] As for lung transplant recipients and other conditions requiring chemotherapy (solid tumors) or chronic immunosuppression, there is limited data supporting its use on them.[150] Interestingly,[152] oral ribavirin was reported as the only factor associated with reduced mortality (HR=0.19) in a non-immunocompromised adult cohort of RSV-hospitalized patients.

Palivizumab, a specific RSV monoclonal antibody historically used for passive immunoprophylaxis among preterms and some other high-risk pediatric populations, has been described as off-label immunomodulator treatment alone or in combination with ribavirin for RSV-infected high-risk children.[153] Intravenous immunoglobulin (with or without palivizumab) also has been used as co-adjuvant therapy in some lung and heart-lung transplant recipients[154] but there is insufficient evidence of the use of these immunoglobulins for the treatment of severe RSV infection. The administration of hyperimmune immunoglobulin, non-specific immunoglobulins containing high antibody titers against a range of respiratory viral pathogens of concern, has also been reported in children on MV with high support.[132]

Multiple investigational drugs against specific RSV viral compounds are currently in development.[18] Fusion inhibitors (rilematovir, presatovir, and sisunatovir), seem to have good safety profiles and efficacy in reducing viral load, showing promise against RSV disease when administered in early stages. The role of all the above therapies and future antiviral therapies in severe RSV disease will be determined in the next few years, depending on the success of the new emerging forms of prevention for RSV disease: Arexvy (GSK, Middlesex, UK), Abrysvo (Pfizer, NY, USA) vaccines, and the recently approved long-acting monoclonal antibody against RSV – nirsevimab – for passive immunity, which offered around 80% protection against severe disease among infants who were 12 months of age or younger before entering their first RSV season.[155]

Antibiotic practices in severe RSV disease

In an era where antibiotic stewardship is emphasized to preserve antibiotic efficacy, reduce costs, and limit toxicity, antibiotic prescribing practices among patients with viral respiratory infections are concerning (33%–87%).[156,157] Among 1016 RSV-hospitalized children, an increased likelihood for antibiotic misuse was associated with variables indicative of severe patient status such as lower oxygen saturation.[157] Despite recent research linking the presence of some potential pathogen respiratory microbiota with severe RSV disease, current evidence does not support universal antibiotic therapy in LRTI-RVS with respiratory failure.[69,158] Among 11,029 children with bronchiolitis admitted to the ICU for NIV, Ortmann et al.[159] did not find better clinical outcomes with early antibiotic use. The interaction between the respiratory microbiota and RSV seems to be more complex, enhancing the potential damage caused by the virus when baseline microbiota profiles are lost and replaced by the abundance of potential pathogens, more than by the potential pathogens by themselves. Antibiotics could also add more harm in most cases. Nevertheless, co-bacterial infection is reported around 25% of RSV episodes among critically ill adults and children, being associated with worse outcomes in both populations.[22,85,152,156] A prudent approach to identify and optimally treat bacterial co-infection is needed.[158] Clinicians frequently are reluctant to discontinue antibiotics in critically ill-patients, especially in those severely hypoxemic, since the diagnosis of secondary bacterial pulmonary infection is often challenging. Interestingly, antibiotic overuse has been reported to be more frequent in adults than in children with RSV or other viral LRTI (37% vs. 87%).[160,161] The increased consumption of antibiotics during the COVID-19 pandemic posed a threat for antimicrobial resistance exacerbation.[162,163] Efforts to identify a real bacterial co-/superinfection using white cell counts and other blood biomarkers have been reported.[164,165] Among them, procalcitonin has been proved to be more sensitive and specific than C-reactive protein reactive in detecting bacterial infection in infants with severe bronchiolitis admitted to the ICU.[164] Implementation of procalcitonin cut-off values inside the framework of specific stewardship programs, and the proper categorization of each severe RSV disease may prevent unnecessary antibiotic use and other invasive diagnostic procedures. Limitations of the present studies include the under-characterization of the spectrum of the RSV disease, without discrimination from exacerbations of previous pulmonary conditions, and the difficulty for an accurate diagnosis of bacterial pneumonia, especially in patients on MV. Moreover, early ventilator-associated pneumonia (superinfection) frequently shares some of the causative microorganisms with the most frequent co-infections and microbiota profiles associated with severe RSV. Further research characterizing the changes in the microbiota and host response in lower tract respiratory samples is needed to elucidate its role in mixed infections and the most severe RSV disease development.

Conclusions

RSV affects individuals of all ages and manifests as a heterogeneous disease with a wide spectrum of severity, influenced by age and other factors. While most RSV hospitalizations involve bronchiolitis in healthy infants, the disease extends beyond this age group and phenotype. Compared to children, a significant portion of hospitalized adults, especially those with underlying cardiopulmonary conditions, immunosuppression, or other less recognized risk factors (diabetes, chronic renal disease) require intensive care. The main risk factors for severe disease usually correlate with worse outcomes. Currently, supportive care constitutes the primary treatment approach for RSV infection. Distinguishing RSV-induced wheezing from respiratory tract thickening, unresponsive to bronchodilators, is crucial. Additionally, obstructive RSV may coexist with viral pneumonia and progress to severe hypoxemic disease. The role of microbiome profiles in severe RSV disease development, amplifying viral damage capacity and increasing susceptibility to secondary bacterial infections, is becoming increasingly apparent. Respiratory support for RSV-infected patients requiring intensive care ranges from HFNC to ECMO support. NIV and HFNC are emerging as important modalities, particularly in specific phenotypes in the adult population, mirroring their efficacy in children. A comprehensive characterization of RSV disease phenotypes and pathophysiology holds promise for optimizing management strategies and comparing outcomes. Bacterial co-infections are associated with worse outcomes in both pediatric and adult populations, although their accurate diagnosis remains challenging. Current evidence and antibiotic stewardship policies discourage indiscriminate antibiotic practices, even in severe cases. The role of currently-in-development antiviral therapies for RSV disease hinges on the success of new vaccines and immune passive strategies with nirsevimab.

Author Contributions

Yolanda Peña-López: Writing – original draft, Conceptualization. Joan Sabater-Riera: Writing – review & editing, Writing – original draft. Prithvi Raj: Writing – review & editing.

Acknowledgment

The authors acknowledge Kristin Hutcheson for editing the final manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics Statement

This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Availability

The data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
==== Refs
References

1 Rao S. Armistead I. Messacar K. Alden N.B. Schmoll E. Austin E. Shifting epidemiology and severity of respiratory syncytial virus in children during the COVID-19 pandemic JAMA Pediatr 177 7 2023 730 732 10.1001/jamapediatrics.2023.1088 37184852
2 Faraguna M.C. Lepri I. Clavenna A. Bonati M. Vimercati C. Sala D. The bronchiolitis epidemic in 2021-2022 during the SARS-CoV-2 pandemic: experience of a third level centre in Northern Italy Ital J Pediatr 49 1 2023 26 10.1186/s13052-023-01425-8 36803828
3 Hönemann M. Thiem S. Bergs S. Berthold T. Propach C. Siekmeyer M. In-depth analysis of the re-emergence of respiratory syncytial virus at a tertiary care hospital in Germany in the summer of 2021 after the alleviation of non-pharmaceutical interventions due to the SARS-CoV-2 pandemic Viruses 15 4 2023 877 10.3390/v15040877 37112857
4 Narejos Pérez S. Ramón Torrell J.M. Põder A. Leroux-Roels I. Pérez-Breva L. Steenackers K. Respiratory syncytial virus disease burden in community-dwelling and long-term care facility older adults in Europe and the United States: a prospective study Open Forum Infect Dis 10 4 2023 ofad111 10.1093/ofid/ofad111 37065988
5 Wilkinson T. Beaver S. Macartney M. McArthur E. Yadav V. Lied-Lied A. Burden of respiratory syncytial virus in adults in the United Kingdom: a systematic literature review and gap analysis Influenza Other Respir Viruses 17 9 2023 e13188 10.1111/irv.13188 37744994
6 Juhn Y.J. Wi C.I. Takahashi P.Y. Ryu E. King K.S. Hickman J.A. Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 pandemic JAMA Netw Open 6 1 2023 e2250634 10.1001/jamanetworkopen.2022.50634
7 Phetsouphanh C. Darley D.R. Wilson D.B. Howe A. Munier C.M.L. Patel S.K. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection Nat Immunol 23 2 2022 210 10.1038/s41590-021-01113-x 35027728
8 Parums D.V. Editorial: long-term effects of symptomatic and asymptomatic SARS-CoV-2 infection in children and the changing pathogenesis of common childhood viruses driven by the COVID-19 pandemic Med Sci Monit 28 2022 e937927 10.12659/MSM.937927
9 Abu-Raya B. Viñeta Paramo M. Reicherz F. Lavoie P.M Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine 61 2023 102089 10.1016/j.eclinm.2023.102089
10 Niekler P. Goettler D. Liese J.G. Streng A. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019) Infection 2023 10.1007/s15010-023-02122-8
11 Busack B. Shorr A.F. Going viral-RSV as the neglected adult respiratory virus Pathogens 11 11 2022 1324 10.3390/pathogens11111324 36422576
12 Kim T. Huh J.W. Hong S.B. Jung J. Kim M.J. Chong Y.P. Epidemiology and characteristics of respiratory syncytial virus pneumonia in critically ill adults Open Forum Infect Dis 10 4 2023 ofad131 10.1093/ofid/ofad131 37035491
13 Englund J.A. Cohen R.A. Bianco V. Domachowske J.B. Langley J.M. Madhi S.A. Evaluation of clinical case definitions for respiratory syncytial virus lower respiratory tract infection in young children J Pediatr Infect Dis Soc 12 5 2023 273 281 10.1093/jpids/piad028
14 Sheikh Z. Potter E. Li Y. Cohen R.A. Dos Santos G. Bont L. Validity of clinical severity scores for respiratory syncytial virus: a systematic review J Infect Dis 229 Suppl_1 2024 S8 17 10.1093/infdis/jiad436 37797314
15 Osborne R.H. Nelson L.M. Fehnel S. Williams N. Bender R.H. Ziemiecki R. Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the respiratory infection intensity and impact QuestionnaireTM symptom scores J Patient Rep Outcomes 7 1 2023 51 10.1186/s41687-023-00593-9 37261682
16 Hirve S. Crawford N. Palekar R. Zhang W. The WHO RSV Surveillance Group. Clinical characteristics, predictors, and performance of case definition – interim results from the WHO global respiratory syncytial virus surveillance pilot Influenza Other Respir Viruses 14 6 2020 647 657 10.1111/irv.12688 31670892
17 Bouzid D. Visseaux B. Ferré V.M. Peiffer-Smadja N. Le Hingrat Q. Loubet P Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments Clin Microbiol Infect 29 12 2023 1538 1550 10.1016/j.cmi.2023.08.028 37666450
18 Zou G. Cao S. Gao Z. Yie J. Wu J.Z. Current state and challenges in respiratory syncytial virus drug discovery and development Antiviral Res 221 2024 105791 10.1016/j.antiviral.2023.105791
19 Feinstein Y. Greenberg D. Ben-Shimol S. Mimran M. Dagan R. Givon-Lavi N. Characterization of children younger than 5 years of age with severe community-acquired alveolar pneumonia (CAAP) requiring pediatric intensive care unit (PICU) admission Pediatr Neonatol 61 4 2020 40613 10.1016/j.pedneo.2020.03.011
20 Rao S. Armistead I. Tyler A. Lensing M. Dominguez S.R. Alden N.B. Respiratory syncytial virus, influenza, and coronavirus disease 2019 hospitalizations in children in Colorado during the 2021-2022 respiratory virus season J Pediatr 260 2023 113491 10.1016/j.jpeds.2023.113491
21 Ghazaly M.M.H. Abu Faddan N.H. Raafat D.M. Mohammed N.A. Nadel S Acute viral bronchiolitis as a cause of pediatric acute respiratory distress syndrome Eur J Pediatr 180 4 2021 1229 1234 10.1007/s00431-020-03852-9 33161501
22 Celante H. Oubaya N. Fourati S. Beaune S. Khellaf M. Casalino E. Prognosis of hospitalised adult patients with respiratory syncytial virus infection: a multicentre retrospective cohort study Clin Microbiol Infect 29 7 2023 10.1016/j.cmi.2023.03.003 e1–943
23 Loubet P. Fernandes J. De Pouvourville G. Sosnowiez K. Elong A. Guilmet C. Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: a national hospital database study J Clin Virol 171 2024 105635 10.1016/j.jcv.2023.10563
24 Schmidt H. Das A. Nam H. Yang A. Ison M.G. Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: a 6-year retrospective study Influenza Other Respir Viruses 13 4 2019 331 338 10.1111/irv.12643 30977284
25 Ambrosch A. Luber D. Klawonn F. Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A/B and the original SARS-CoV-2 strain J Clin Virol 161 2023 105399 10.1016/j.jcv.2023.105399
26 Surie D. Yuengling K.A. DeCuir J. Zhu Y. Gaglani M. Ginde A.A. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 years – IVY network, 20U.S. States, February 2022-May 2023 MMWR Morb Mortal Wkly Rep 72 40 2023 1083 1088 10.15585/mmwr.mm7240a2 37796753
27 Asner S. Stephens D. Pedulla P. Richardson S.E. Robinson J. Allen U Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children Pediatr Infect Dis J 32 10 2013 1073 1076 10.1097/INF.0b013e31829dff4d 23732222
28 Walsh E. Lee N. Sander I. Stolper R. Zakar J. Wyffels V. RSV-associated hospitalization in adults in the USA: a retrospective chart review investigating burden, management strategies, and outcomes Health Sci Rep 5 3 2022 e556 10.1002/hsr2.556 35509398
29 DeMartino J.K. Lafeuille M.H. Emond B. Rossi C. Wang J. Liu S. Respiratory syncytial virus-related complications and healthcare costs among a medicare-insured population in the United States Open Forum Infect Dis 10 5 2023 ofad203 10.1093/ofid/ofad203 37213421
30 Shmueli E. Goldberg O. Mei-Zahav M. Stafler P. Bar-On O. Levine H. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases Pediatr Pulmonol 56 7 2021 2204 2211 10.1002/ppul.25435 33913611
31 Grimaldi M. Cornet B. Milou C. Gouyon J.B. Étude prospective régionale d'une épidémie de bronchiolites à virus respiratoire syncytial (VRS) Arch Pédiatr 9 6 2002 572 580 10.1016/s0929-693x(01)00923-x 12108310
32 Nygaard U. Hartling U.B. Nielsen J. Vestergaard L.S. Dungu K.H.S. Nielsen J.S.A. Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study Lancet Child Adolesc Health 7 3 2023 171 179 10.1016/S2352-4642(22)00371-6 36634692
33 Hill-Ricciuti A. Walsh E.E. Greendyke W.G. Choi Y. Barrett A. Alba L. Clinical impact of healthcare-associated respiratory syncytial virus in hospitalized adults Infect Control Hosp Epidemiol 44 3 2023 433 439 10.1017/ice.2022.128 36372395
34 Saiman L. Coffin S.E. Kociolek L.K. Zerr D.M. Milstone A.M. Aldrich M.L. Healthcare-associated respiratory syncytial virus in children's hospitals J Pediatr Infect Dis Soc 12 5 2023 265 272 10.1093/jpids/piad030
35 Nowalk M.P. D'Agostino H. Dauer K. Stiegler M. Zimmerman R.K. Balasubramani G.K Estimating the burden of adult hospitalized RSV infection including special populations Vaccine 40 31 2022 4121 4127 10.1016/j.vaccine.2022.05.077 35667912
36 Tian J. Liu C. Wang X. Zhang L. Zhong G. Huang G. Comparative analysis of clinical features of lower respiratory tract infection with respiratory syncytial virus and influenza virus in adults: a retrospective study BMC Pulm Med 23 1 2023 350 10.1186/s12890-023-02648-5 37715219
37 Coussement J. Zuber B. Garrigues E. Gros A. Vandueren C. Epaillard N. Characteristics and outcomes of patients in the ICU with respiratory syncytial virus compared with those with influenza infection Chest 161 6 2022 1475 1484 10.1016/j.chest.2021.12.670 35063450
38 Shi T. Vennard S. Jasiewicz F. Brogden R. Nair H. investigators RESCEU Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis J Infect Dis 226 Suppl 1 2022 S17 S21 10.1093/infdis/jiab040 34522961
39 Sivgin H. Cetin S. Ulgen A. Li W. Diabetes and bacterial co-infection are two independent risk factors for respiratory syncytial virus disease severity Front Med 10 2023 1231641 10.3389/fmed.2023.123164
40 Chatzis O. Darbre S. Pasquier J. Meylan P. Manuel O. Aubert J.D. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study BMC Infect Dis 18 1 2018 111 10.1186/s12879-018-3002-3 29510663
41 Heinonen S. Süvari L. Gissler M. Pitkänen O. Andersson S. Helve O Transient tachypnea of the newborn is associated with an increased risk of hospitalization due to respiratory syncytial virus bronchiolitis Pediatr Infect Dis J 38 4 2019 419 421 10.1097/INF.0000000000002057 30882737
42 Meenaghan S. Breatnach C. Smith H. Risk factors for respiratory syncytial virus bronchiolitis admissions Ir Med J 113 1 2020 9 32298565
43 van Hasselt T.J. Webster K. Gale C. Draper E.S. Seaton S.E. Children born preterm admitted to paediatric intensive care for bronchiolitis: a systematic review and meta-analysis BMC Pediatr 23 1 2023 326 10.1186/s12887-023-04150-7 37386478
44 Chan M. Park J.J. Shi T. Martinón-Torres F. Bont L. Nair H. The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with down syndrome: a systematic review and meta-analysis J Glob Health 7 2 2017 020413 10.7189/jogh.07.020413
45 Chu F.L. Li C. Chen L. Dong B. Qiu Y. Liu Y. Respiratory viruses among pediatric inpatients with acute lower respiratory tract infections in Jinan, China, 2016-2019 J Med Virol 94 9 2022 4319 4328 10.1002/jmv.27875 35593042
46 Halasa N. Zambrano L.D. Amarin J.Z. Stewart L.S. Newhams M.M. Levy E.R. Infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak JAMA Netw Open 6 8 2023 e2328950 10.1001/jamanetworkopen.2023.28950
47 Ciarlitto C. Vittucci A.C. Antilici L. Concato C. Di Camillo C. Zangari P. Respiratory syncityal virus A and B: three bronchiolitis seasons in a third level hospital in Italy Ital J Pediatr 45 1 2019 115 10.1186/s13052-019-0704-0 31462274
48 Martinello R.A. Chen M.D. Weibel C. Kahn J.S. Correlation between respiratory syncytial virus genotype and severity of illness J Infect Dis 186 6 2002 839 842 10.1086/342414 12198620
49 Munywoki P.K. Koech D.C. Agoti C.N. Kibirige N. Kipkoech J. Cane P.A. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding Epidemiol Infect 143 4 2015 804 812 10.1017/S0950268814001393 24901443
50 Bay P. Loegel C. Ly A. Soulier A. N'Debi M. Seng S. Clinical phenotypes and molecular characteristics of respiratory syncytial virus in adults: a monocentric prospective study between 2019 and 2022 J Infect Dis 2023 jiad479 10.1093/infdis/jiad479
51 Garcia-Mauriño C. Moore-Clingenpeel M. Thomas J. Mertz S. Cohen D.M. Ramilo O. Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection J Infect Dis 219 8 2019 1207 1215 10.1093/infdis/jiy655 30418604
52 Li Y. Pillai P. Miyake F. Nair H. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis J Glob Health 10 1 2020 010426 10.7189/jogh.10.010426
53 Crowe J.E. Williams J.V. Paramyxoviruses: respiratory syncytial virus and human metapneumovirus Kaslow RA Stanberry LR. Le Duc JW Viral infections of humans 2014 Published 601 627 10.1007/978-1-4899-7448-8_26 2014 Feb 27
54 Zhang Y. Zhao J. Zou X. Fan Y. Xiong Z. Li B. Severity of influenza virus and respiratory syncytial virus coinfections in hospitalized adult patients J Clin Virol 133 2020 104685 10.1016/j.jcv.2020.104685
55 Li Y. Johnson E.K. Shi T. Campbell H. Chaves S.S. Commaille-Chapus C. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study Lancet Respir Med 9 2 2021 175 185 10.1016/S2213-2600(20)30322-2 32971018
56 Estofolete C.F. Banho C.A. Verro A.T. Gandolfi F.A. Dos Santos B.F. Sacchetto L. Clinical characterization of respiratory syncytial virus infection in adults: a neglected disease? Viruses 15 9 2023 1848 10.3390/v15091848 37766255
57 Tongyoo S. Naorungroj T. Laikitmongkhon J. Predictive factors and outcomes of respiratory syncytial virus infection among patients with respiratory failure Front Med 10 2023 1148531 10.3389/fmed.2023.1148531
58 Flamant C. Hallalel F. Nolent P. Chevalier J.Y. Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation Eur J Pediatr 164 2 2005 93 98 10.1007/s00431-004-1580-0 15703980
59 Schroeder A.R. Destino L.A. Ip W. Vukin E. Brooks R. Stoddard G. Day of illness and outcomes in bronchiolitis hospitalizations Pediatrics 146 5 2020 e20201537 10.1542/peds.2020-1537
60 Rodriguez-Martinez C.E. Barbosa-Ramirez J. Acuña-Cordero R Predictors of poor outcomes of respiratory syncytial virus acute lower respiratory infections in children under 5 years of age in a middle-income tropical country based on the national public health surveillance system Pediatr Pulmonol 57 5 2022 1188 1195 10.1002/ppul.25866 35182056
61 Rodríguez-Martínez C.E. Castro-Rodriguez J.A. Nino G. Midulla F. The impact of viral bronchiolitis phenotyping: is it time to consider phenotype-specific responses to individualize pharmacological management? Paediatr Respir Rev 34 2020 53 58 10.1016/j.prrv.2019.04.003 31054799
62 Descamps A. Lenzi N. Galtier F. Lainé F. Lesieur Z. Vanhems P. In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017–2019: an observational study Eur Respir J 59 3 2022 2100651 10.1183/13993003.00651-2021
63 Falsey A.R. Hennessey P.A. Formica M.A. Cox C. Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults N Engl J Med 352 17 2005 1749 1759 10.1056/NEJMoa043951 15858184
64 ElSherif M. Andrew M.K. Ye L. Ambrose A. Boivin G. Bowie W. Leveraging influenza virus surveillance from 2012 to 2015 to characterize the burden of respiratory syncytial virus disease in Canadian adults ≥50 years of age hospitalized with acute respiratory illness Open Forum Infect Dis 10 7 2023 ofad315 10.1093/ofid/ofad315 37441353
65 Tin Tin Htar M. Yerramalla M.S. Moïsi J.C. Swerdlow D.L. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis Epidemiol Infect 148 2020 e48 10.1017/S0950268820000400 32052719
66 Rozenbaum M.H. Begier E. Kurosky S.K. Whelan J. Bem D. Pouwels K.B. Incidence of respiratory syncytial virus infection in older adults: limitations of current data Infect Dis Ther 12 6 2023 1487 1504 10.1007/s40121-023-00802-4 37310617
67 Rello J. Sabater-Riera J. Challenges in respiratory syncytial virus in adults with severe community-acquired pneumonia Chest 161 6 2022 1434 1435 10.1016/j.chest.2022.01.050 35680305
68 Robert D. Verbiest D. Demey H. Ieven M. Jansens H. Jorens P.G. A series of five adult cases of respiratory syncytial virus-related acute respiratory distress syndrome Anaesth Intensive Care 36 2 2008 230 234 10.1177/0310057x0803600214 18361015
69 Ravindranath T.M. Gomez A. Harwayne-Gidansky I. Connors T.J. Neill N. Levin B. Pediatric acute respiratory distress syndrome associated with human metapneumovirus and respiratory syncytial virus Pediatr Pulmonol 53 7 2018 929 935 10.1002/ppul.24044 29737017
70 Hammer J. Numa A. Newth C.J. Acute respiratory distress syndrome caused by respiratory syncytial virus Pediatr Pulmonol 23 3 1997 176 183 10.1002/(sici)1099-0496(199703)23:3<176:aid-ppul2>3.0.co;2-m 9094725
71 Farias J.A. Frutos-Vivar F. Casado Flores J. Siaba A. Retta A. Fernández A. Factors associated with the prognosis of mechanically ventilated infants and children. An international study Med Intensiva 30 9 2006 425 431 10.1016/s0210-5691(06)74565-x 17194399
72 Máca J. Jor O. Holub M. Sklienka P. Burša F. Burda M. Past and present ARDS mortality rates: a systematic review Respir Care 62 1 2017 113 122 10.4187/respcare.04716 27803355
73 Meyer N.J. Gattinoni L. Calfee C.S. Acute respiratory distress syndrome Lancet 398 10300 2021 622 637 10.1016/S0140-6736(21)00439-6 34217425
74 Ghosh A. Annigeri S. Hemram S.K. Dey P.K. Mazumder S. Clinico-demographic profile and predictors of intensive care need in children with respiratory syncytial virus-associated acute lower respiratory illness during its recent outbreak alongside ongoing COVID-19 pandemic: an Eastern Indian perspective Indian J Crit Care Med 26 11 2022 1210 1217 10.5005/jp-journals-10071-24350 36873591
75 Patel N. AL-Sayyed B. Gladfelter T. Tripathi S. Epidemiology and outcomes of bacterial coinfection in hospitalized children with respiratory viral infections: a single center retrospective chart review J Pediatr Pharmacol Ther 27 6 2022 529 536 10.5863/1551-6776-27.6.529 36042958
76 Wongsurakiat P. Sunhapanit S. Muangman N. Bacterial coinfection and superinfection in respiratory syncytial virus-associated acute respiratory illness: prevalence, pathogens, initial antibiotic-prescribing patterns and outcomes Tropical Med Infect Dis 8 3 2023 148 10.3390/tropicalmed8030148
77 Dumas G. Bertrand M. Lemiale V. Canet E. Barbier F. Kouatchet A. Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure Ann Intensive Care 13 1 2023 101 10.1186/s13613-023-01196-9 37833435
78 Prill M.M. Langley G.E. Winn A. Gerber S.I. Respiratory syncytial virus-associated deaths in the United States according to death certificate data, 2005 to 2016 Health Sci Rep 4 4 2021 e428 10.1002/hsr2.428 34754948
79 Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection – a systematic review Crit Care 10 4 2006 R107 10.1186/cc4984 16859512
80 Smale M. Freckelton J. Waters M. Grill V. Hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion in adults with respiratory syncytial virus infection Internal Med J 51 8 2021 1340 1343 10.1111/imj.15453 34423538
81 Aljohani O.A. Mackie D. Bratincsak A. Bradley J.S. Perry J.C. Spectrum of viral pathogens identified in children with clinical myocarditis (pre-coronavirus disease-2019, 2000-2018): etiologic agent versus innocent bystander J Pediatr 242 2022 18 24 10.1016/j.jpeds.2021.11.011 34774573
82 Kawashima H. Inagaki N. Nakayama T. Morichi S. Nishimata S. Yamanaka G. Cardiac complications caused by respiratory syncytial virus infection: questionnaire survey and a literature review Glob Pediatr Health 8 2021 2333794 10.1177/2333794x211044114 ×2110441
83 Thorburn K. Fulton C. King C. Ramaneswaran D. Alammar A. McNamara P.S. Transaminase levels reflect disease severity in children ventilated for respiratory syncytial virus (RSV) bronchiolitis Sci Rep 8 1 2018 1803 10.1038/s41598-018-20292-6 29379110
84 Edwards K.D. Tighe M.P. How to use N-terminal pro-brain natriuretic peptide (NT-proBNP) in assessing disease severity in bronchiolitis Arch Dis Child Educ Pract Ed 105 5 2020 282 288 10.1136/archdischild-2019-316896 31615845
85 Lee N. Lui G.C. Wong K.T. Li T.C. Tse E.C. Chan J.Y. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections Clin Infect Dis 57 8 2013 1069 1077 10.1093/cid/cit471 23876395
86 Ivey K.S. Edwards K.M. Talbot H.K. Respiratory syncytial virus and associations with cardiovascular disease in adults J Am Coll Cardiol 71 14 2018 1574 1583 10.1016/j.jacc.2018.02.013 29622165
87 Tian J. Wang X.Y. Zhang L.L. Liu M.J. Ai J.H. Feng G.S. Clinical epidemiology and disease burden of bronchiolitis in hospitalized children in China: a national cross-sectional study World J Pediatr 19 9 2023 851 863 10.1007/s12519-023-00688-9 36795317
88 Bottino P. Miglino R. Pastrone L. Barbui A.M. Botta G. Zanotto E. Clinical features of respiratory syncytial virus bronchiolitis in an infant: rapid and fatal brain involvement BMC Pediatr 21 1 2021 556 10.1186/s12887-021-03045-9 34886830
89 Harding J.N. Siefker D. Vu L. You D. DeVincenzo J. Pierre J.F. Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity BMC Microbiol 20 1 2020 140 10.1186/s12866-020-01816-5 32487019
90 Brealey J.C. Chappell K.J. Galbraith S. Fantino E. Gaydon J. Tozer S. Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children Respirology 23 2 2018 220 227 10.1111/resp.13179 28913912
91 Sulaiman I. Chung M. Angel L. Tsay J.J. Wu B.G. Yeung S.T. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome Nat Microbiol 6 10 2021 1245 1258 10.1038/s41564-021-00961-5 34465900
92 Lee K.H. Gordon A. Shedden K. Kuan G. Ng S. Balmaseda A. The respiratory microbiome and susceptibility to influenza virus infection PLoS One 14 1 2019 e0207898 10.1371/journal.pone.0207898
93 Brealey J.C. Young P.R. Sloots T.P. Ware R.S. Lambert S.B. Sly P.D. Bacterial colonization dynamics associated with respiratory syncytial virus during early childhood Pediatr Pulmonol 55 5 2020 1237 1245 10.1002/ppul.24715 32176838
94 Hasegawa K. Mansbach J.M. Ajami N.J. Petrosino J.F. Freishtat R.J. Teach S.J. Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis J Allergy Clin Immunol 139 4 2017 1383 1386 10.1016/j.jaci.2016.09.03 e6 27845236
95 Su Z. Tao X. Current understanding of IL-37 in human health and disease Front Immunol 12 2021 696605 10.3389/fimmu.2021.696605
96 Cuthbertson L. James P. Habibi M.S. Thwaites R.S. Paras A. Chiu C. Resilience of the respiratory microbiome in controlled adult RSV challenge study Eur Respir J 59 1 2022 2101932 10.1183/13993003.01932-2021
97 Kim C.K. Kim H.B. Kurian T. Chung J.Y. Yoo Y. Koh Y.Y. Increased laryngeal lavage lipid-laden macrophage index during acute bronchiolitis Acta Paediatr 96 7 2007 1025 1029 10.1111/j.1651-2227.2007.00314.x 17498191
98 Barbosa L.D.R. Gomes E. Fischer G.B. [Clinical signs of dysphagia in infants with acute viral bronchiolitis] Rev Paul Pediatr 32 3 2014 157 163 10.1590/0103-0582201432302 25479843
99 Hernandez E. Khoshoo V. Thoppil D. Edell D. Ross G. Aspiration: a factor in rapidly deteriorating bronchiolitis in previously healthy infants? Pediatr Pulmonol 33 1 2002 30 31 10.1002/ppul.10022 11747257
100 Kobiałka M. Jackowska T. Wrotek A. Risk factors for severe respiratory syncytial virus infection in hospitalized children Viruses 15 8 2023 1713 10.3390/v15081713 37632055
101 Takahashi H. Jinguu D. Yajima T. Ubukata S. Shoji M. Watanabe A. Clinical characteristics of adult onset RSV infection during two consecutive winter seasons Kansenshogaku Zasshi 90 5 2016 645 651 10.11150/kansenshogakuzasshi.90.645 30212047
102 Li Z. Li Y. Sun Q. Wei J. Li B. Qiu Y. Targeting the pulmonary microbiota to fight against respiratory diseases Cells 11 5 2022 916 10.3390/cells11050916 35269538
103 Diaz-Diaz A. Bunsow E. Garcia-Maurino C. Moore-Clingenpeel M. Naples J. Juergensen A. Nasopharyngeal codetection of Haemophilus influenzae and Streptococcus pneumoniae shapes respiratory syncytial virus disease outcomes in children J Infect Dis 225 5 2022 912 923 10.1093/infdis/jiab481 34543409
104 Breakell R. Thorndyke B. Clennett J. Harkensee C. Reducing unnecessary chest X-rays, antibiotics and bronchodilators through implementation of the NICE bronchiolitis guideline Eur J Pediatr 177 1 2018 47 51 10.1007/s00431-017-3034-5 29080051
105 Broadbent L. Groves H. Shields M.D. Power U.F. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials Influenza Other Respir Viruses 9 4 2015 169 178 10.1111/irv.12313 25847510
106 Totapally B.R. Demerci C. Zureikat G. Nolan B. Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol [ISRCTN47364493] Crit Care 6 2 2002 160 10.1186/cc1476 11983043
107 Ingelse S.A. Wiegers H.M.G. Calis J.C. van Woensel J.B. Bem R.A. Early fluid overload prolongs mechanical ventilation in children with viral-lower respiratory tract disease Pediatr Crit Care Med 18 3 2017 e106 e111 10.1097/PCC.0000000000001060 28107266
108 Javouhey E. Barats A. Richard N. Stamm D. Floret D. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis Intensive Care Med 34 9 2008 1608 10.1007/s00134-008-1150-4 18500424
109 Marcos-Morales A. García-Salido A. Leoz-Gordillo I. de Lama Caro-Patón G. Martínez de Azagra-Garde A García-Teresa MÁ Respiratory and pharmacological management in severe acute bronchiolitis: were clinical guidelines not written for critical care? Arch Pediatr 28 2 2021 150 155 10.1016/j.arcped.2020.11.007 33339722
110 Clayton J.A. McKee B. Slain K.N. Rotta A.T. Shein S.L. Outcomes of children with bronchiolitis treated with high-flow nasal cannula or noninvasive positive pressure ventilation Pediatr Crit Care Med 20 2 2019 128 135 10.1097/PCC.0000000000001798 30720646
111 Franklin D. Dalziel S. Schlapbach L.J. Babl F.E. Oakley E. Craig S.S. Early high flow nasal cannula therapy in bronchiolitis, a prospective randomised control trial (protocol): a paediatric acute respiratory intervention study (PARIS) BMC Pediatr 15 2015 183 10.1186/s12887-015-0501-x 26572729
112 Mitting R.B. Peshimam N. Lillie J. Donnelly P. Ghazaly M. Nadel S. Invasive mechanical ventilation for acute viral bronchiolitis: retrospective multicenter cohort study Pediatr Crit Care Med 22 3 2021 231 240 10.1097/PCC.0000000000002631 33512983
113 Kooiman L. Blankespoor F. Hofman R. Kamps A. Gorissen M. Vaessen-Verberne A. High-flow oxygen therapy in moderate to severe bronchiolitis: a randomised controlled trial Arch Dis Child 108 6 2023 455 460 10.1136/archdischild-2022-324697 36941030
114 Ghirardo S. Cozzi G. Tonin G. Risso F.M. Dotta L. Zago A. Increased use of high-flow nasal cannulas after the pandemic in bronchiolitis: a more severe disease or a changed physician's attitude? Eur J Pediatr 181 11 2022 3931 3936 10.1007/s00431-022-04601-w 36083314
115 Wiser R.K. Smith A.C. Khallouq B.B. Chen J.G. A pediatric high-flow nasal cannula protocol standardizes initial flow and expedites weaning Pediatr Pulmonol 56 5 2021 1189 1197 10.1002/ppul.25214 33295690
116 Smith A. Banville D. O'Rourke C. Melvin P. Batey L. Borgmann A. Randomized trial of weight-based versus fixed limit high-flow nasal cannula in bronchiolitis Hosp Pediatr 13 5 2023 387 393 10.1542/hpeds.2022-006656 37122050
117 Peterson R.J. Hassumani D.O. Hole A.J. Slaven J.E. Tori A.J. Abu-Sultaneh S. Implementation of a high-flow nasal cannula management protocol in the pediatric ICU Respir Care 66 4 2021 591 599 10.4187/respcare.08284 32917844
118 Solana-Gracia R. Modesto I. Alapont V. Bueso-Inchausti L. Luna-Arana M. Möller-Díez A. Medina A. Changes in ventilation practices for bronchiolitis in the hospital ward and need for ICU transfer over the last decade J Clin Med 11 6 2022 1622 10.3390/jcm11061622 35329951
119 Habra B. Janahi I.A. Dauleh H. Chandra P. Veten A. A comparison between high-flow nasal cannula and noninvasive ventilation in the management of infants and young children with acute bronchiolitis in the PICU Pediatr Pulmonol 55 2 2020 455 461 10.1002/ppul.24553 31922360
120 Agüera M. Melé-Casas M. Molina M.M. Pons-Odena M. de-Sevilla M.F. García-García J.J. Safety and effectiveness of bubble continuous positive airway pressure as respiratory support for bronchiolitis in a pediatric ward Eur J Pediatr 181 12 2022 4039 4047 10.1007/s00431-022-04616-3 36129536
121 Delacroix E. Millet A. Wroblewski I. Vilotitch A. Pin I. Ego A. Has the introduction of high-flow nasal cannula modified the clinical characteristics and outcomes of infants with bronchiolitis admitted to pediatric intensive care units? A retrospective study Arch Pediatr 28 2 2021 141 146 10.1016/j.arcped.2020.11.006 33334653
122 Frat J.P. Thille A.W. Mercat A. Girault C. Ragot S. Perbet S. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure N Engl J Med 372 23 2015 2185 2196 10.1056/NEJMoa1503326 25981908
123 Perkins G.D. Ji C. Connolly B.A. Couper K. Lall R. Baillie J.K. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial JAMA 327 6 2022 546 558 10.1001/jama.2022.0028 35072713
124 Ospina-Tascón G.A. Calderón-Tapia L.E. García A.F. Zarama V. Gómez-Álvarez F. Álvarez-Saa T. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial JAMA 326 21 2021 2161 2171 10.1001/jama.2021.20714 34874419
125 Chawla R. Dixit S.B. Zirpe K.G. Chaudhry D. Khilnani G.C. Mehta Y. ISCCM guidelines for the use of non-invasive ventilation in acute respiratory failure in adult ICUs Indian J Crit Care Med 24 S1 2020 S61 S81 10.5005/jp-journals-10071-G23186 32205957
126 Nair P.R. Haritha D. Behera S. Kayina C.A. Maitra S. Anand R.K. Comparison of high-flow nasal cannula and noninvasive ventilation in acute hypoxemic respiratory failure due to severe COVID-19 pneumonia Respir Care 66 12 2021 1824 1830 10.4187/respcare.09130 34584010
127 Sun G.C. Aljareh A. Khan Z. Bachan M. Adult respiratory syncytial virus infection and non-invasive ventilation in respiratory failure B50 cases in pulmonary critical care 2023 American Thoracic Society A3568 10.1164/ajrccmconference.2023.207.1_MeetingAbstracts.A3568 3568
128 Arabi Y.M. Fowler R. Hayden F.G. Critical care management of adults with community-acquired severe respiratory viral infection Intensive Care Med 46 2 2020 315 328 10.1007/s00134-020-05943-5 32040667
129 Cruces P. González-Dambrauskas S. Quilodrán J. Valenzuela J. Martínez J. Rivero N. Respiratory mechanics in infants with severe bronchiolitis on controlled mechanical ventilation BMC Pulm Med 17 1 2017 129 10.1186/s12890-017-0475-6 28985727
130 Greenough A. Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO Paediatr Respir Rev 10 2009 26 28 10.1016/S1526-0542(09)70012-0 19651398
131 Grasselli G. Calfee C.S. Camporota L. Poole D. Amato M.B.P. Antonelli M. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies Intensive Care Med 49 7 2023 727 759 10.1007/s00134-023-07050-7 37326646
132 Emeriaud G. López-Fernández Y.M. Iyer N.P. Bembea M.M. Agulnik A. Barbaro R.P. Executive summary of the second international guidelines for the diagnosis and management of pediatric acute respiratory distress syndrome (PALICC-2) Pediatr Crit Care Med 24 2 2023 143 168 10.1097/PCC.0000000000003147 36661420
133 Sinha P. Calfee C.S. Phenotypes in acute respiratory distress syndrome: moving towards precision medicine Curr Opin Crit Care 25 1 2019 12 20 10.1097/MCC.0000000000000571 30531367
134 Demoule A. Brochard L. Dres M. Heunks L. Jubran A. Laghi F. How to ventilate obstructive and asthmatic patients Intensive Care Med 46 12 2020 2436 2449 10.1007/s00134-020-06291-0 33169215
135 Rosén J. von Oelreich E. Fors D. Jonsson Fagerlund M. Taxbro K. Skorup P. Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial Crit Care 25 1 2021 209 10.1186/s13054-021-03602-9 34127046
136 Chen Z. Li M. Gu S. Huang X. Xia J. Ye Q. Effect of prone position in patients with acute respiratory distress syndrome supported by venovenous extracorporeal membrane oxygenation: a retrospective cohort study BMC Pulm Med 22 1 2022 234 10.1186/s12890-022-02026-7 35710365
137 Selin S. Mecklin M. Korppi M. Heikkilä P. Twenty-one-year follow-up revealed guideline-concordant and non-concordant trends in intensive care of bronchiolitis Eur J Pediatr 182 6 2023 2665 2671 10.1007/s00431-023-04940-2 36988679
138 Stobbelaar K. Kool M. de Kruijf D. Van Hoorenbeeck K. Jorens P. De Dooy J. Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: a retrospective study J Paediatr Child Health 55 9 2019 1125 1132 10.1111/jpc.14371 30645038
139 Hsieh C.W. Chen C. Su H.C. Chen K.H. Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials BMC Pediatr 20 1 2020 434 10.1186/s12887-020-02314-3 32928154
140 Zhang L. Mendoza-Sassi R.A. Wainwright C.E. Aregbesola A. Klassen T.P. Nebulised hypertonic saline solution for acute bronchiolitis in infants Cochrane Database Syst Rev 4 4 2023 CD006458 10.1002/14651858.CD006458.pub5
141 Vettleson K. Heiberger A. Olgun G. Dornase alfa in mechanically ventilated children with bronchiolitis: a retrospective cohort study Pediatr Pulmonol 58 8 2023 2283 2288 10.1002/ppul.26481 37204223
142 Linssen R.S.N. Ma J. Bem R.A. Rubin B.K. Rational use of mucoactive medications to treat pediatric airway disease Paediatr Respir Rev 36 2020 8 14 10.1016/j.prrv.2020.06.007 32653467
143 Blakeman T.C. Scott J.B. Yoder M.A. Capellari E. Strickland S.L. AARC clinical practice guidelines: artificial airway suctioning Respir Care 67 2 2022 258 271 10.4187/respcare.09548 35078900
144 O'Neal P.V. Grap M.J. Thompson C. Dudley W. Level of dyspnoea experienced in mechanically ventilated adults with and without saline instillation prior to endotracheal suctioning Intensive Crit Care Nurs 17 6 2001 356 363 10.1054/iccn.2001.1604 11853012
145 Roqué-Figuls M. Giné-Garriga M. Granados Rugeles C. Perrotta C. Vilaró J Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old Cochrane Database Syst Rev 4 4 2023 CD004873 10.1002/14651858.CD004873.pub6
146 Huang H.P. Chen K.H. Tsai C.L. Chang W.P. Chiu S.Y. Lin S.R. Effects of high-frequency chest wall oscillation on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials Int J Chron Obstruct Pulmon Dis 17 2022 2857 2869 10.2147/COPD.S378642 36381994
147 Chen X. Jiang J. Wang R. Fu H. Lu J. Yang M. Chest physiotherapy for pneumonia in adults Cochrane Database Syst Rev 9 2022 CD006338 10.1002/14651858.CD006338.pub4
148 Hoover J. Eades S. Lam W.M. Pediatric antiviral stewardship: defining the potential role of ribavirin in respiratory syncytial virus-associated lower respiratory illness J Pediatr Pharmacol Ther 23 5 2018 372 378 10.5863/1551-6776-23.5.372 30429691
149 Sargel C.L. Aboud M. Forster A. Langman L.J. Tansmore J. Mueller B.A. Intravenous ribavirin for parainfluenza and respiratory syncytial virus in an infant receiving extracorporeal membrane oxygenation and continuous renal replacement therapy J Pediatr Pharmacol Ther 23 4 2018 337 342 10.5863/1551-6776-23.4.337 30181726
150 Tejada S. Martinez-Reviejo R. Karakoc H.N. Peña-López Y. Manuel O. Rello J. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis Adv Ther 39 9 2022 4037 4051 10.1007/s12325-022-02256-5 35876973
151 Manothummetha K. Mongkolkaew T. Tovichayathamrong P. Boonyawairote R. Meejun T. Srisurapanont K. Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis Clin Microbiol Infect 29 10 2023 1272 1279 10.1016/j.cmi.2023.04.021 37116860
152 Wongsurakiat P. Sunhapanit S. Muangman N. Respiratory syncytial virus-associated acute respiratory illness in adult non-immunocompromised patients: outcomes, determinants of outcomes, and the effect of oral ribavirin treatment Influenza Other Respir Viruses 16 4 2022 767 779 10.1111/irv.12971 35150065
153 Chávez-Bueno S. Mejías A. Merryman R.A. Ahmad N. Jafri H.S. Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients Pediatr Infect Dis J 26 12 2007 1089 1093 10.1097/INF.0b013e3181343b7e 18043443
154 Liu V. Dhillon G.S. Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients Transpl Infect Dis 12 1 2010 38 44 10.1111/j.1399-3062.2009.00453.x 19761558
155 Drysdale S.B. Cathie K. Flamein F. Knuf M. Collins A.M. Hill H.C. Nirsevimab for prevention of hospitalizations due to RSV in infants N Engl J Med 389 26 2023 2425 2435 10.1056/NEJMoa2309189 38157500
156 Hayotte A. Mariani-Kurkdjian P. Boizeau P. Dauger S. Riaud C. Lacarra B. Viral identification using multiplex polymerase chain reaction testing does not reduce antibiotic prescribing in paediatric intensive care units Microorganisms 11 4 2023 884 10.3390/microorganisms11040884 37110306
157 Obolski U. Kassem E. Na'amnih W. Tannous S. Kagan V. Muhsen K Unnecessary antibiotic treatment of children hospitalised with respiratory syncytial virus (RSV) bronchiolitis: risk factors and prescription patterns J Glob Antimicrob Resist 27 2021 303 308 10.1016/j.jgar.2021.10.015 34718202
158 Shein S.L. Kong M. McKee B. O'Riordan M. Toltzis P. Randolph A.G. Antibiotic prescription in young children with respiratory syncytial virus–associated respiratory failure and associated outcomes Pediatr Crit Care Med 20 2 2019 101 109 10.1097/PCC.0000000000001839 30720644
159 Ortmann L.A. Nabower A. Cullimore M.L. Kerns E. Antibiotic use in nonintubated children with bronchiolitis in the intensive care unit Pediatr Pulmonol 58 3 2023 804 810 10.1002/ppul.26256 36440528
160 van Houten C.B. Cohen A. Engelhard D. Hays J.P. Karlsson R. Moore E. Antibiotic misuse in respiratory tract infections in children and adults – a prospective, multicentre study (TAILORED treatment) Eur J Clin Microbiol Infect Dis 38 3 2019 505 514 10.1007/s10096-018-03454-2 30707378
161 Volling C. Hassan K. Mazzulli T. Green K. Al-Den A. Hunter P. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study BMC Infect Dis 14 1 2014 665 10.1186/s12879-014-0665-2 25494918
162 Malik S.S. Mundra S. Increasing consumption of antibiotics during the COVID-19 pandemic: implications for patient health and emerging anti-microbial resistance Antibiotics 12 1 2022 45 10.3390/antibiotics12010045 36671246
163 Nandi A. Pecetta S. Bloom D.E. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022 eClinicalMedicine 57 2023 101848 10.1016/j.eclinm.2023.101848
164 Alejandre C. Guitart C. Balaguer M. Torrús I. Bobillo-Perez S. Cambra F.J. Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis Eur J Pediatr 180 3 2021 833 842 10.1007/s00431-020-03790-6 32929531
165 Sierra-Colomina M. García-Salido A. Leoz-Gordillo I. Martínez de Azagra-Garde A. Melen G. García-Teresa M.Á. sRAGE as severe acute bronchiolitis biomarker, prospective observational study Pediatr Pulmonol 55 12 2020 3429 3436 10.1002/ppul.25048 32852101
